Pharma2Care: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Pharma2Care
Largest movements
- Receivables within one year +€427,668
up €427,668 (+29.0%), from €1.5m to €1.9m
of which Other amounts receivable: +€465,501
- Tangible fixed assets -€41,278
down €41,278 (-28.9%), from €142,716 to €101,438
of which Land and buildings: -€40,548
- Short-term financial debts +€464,122
up €464,122 (+163%), from €285,334 to €749,456
- Other debts +€179,988
up €179,988 (+107,462%), from €167 to €180,155
- Debts after one year -€97,566
no longer reported in 2024 (was €97,566)
- Profit (loss) carried forward -€92,638
down €92,638 (-47.6%), from -€194,600 to -€287,237
- Current portion of long-term debt -€52,527
no longer reported in 2024 (was €52,527)
- Gross operating margin -€170,562
down €170,562, from €160,783 to -€9,779
- Depreciation -€102,271
down €102,271 (-68.3%), from €149,793 to €47,522
- Staff costs -€40,003
no longer reported in 2024 (was €40,003)
- Financial charges +€15,011
up €15,011 (+96.0%), from €15,631 to €30,642
- Other operating charges -€2,008
down €2,008 (-30.0%), from €6,704 to €4,696
From the 2023 result to the 2024 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2023 and 2024 balance sheets and the 2024 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2023 | 2024 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,635,944 | €2,011,903 | +€375,959 | +23.0% |
| Fixed assets | 21/28 | €149,122 | €107,844 | -€41,278 | -27.7% |
| Intangible fixed assets | 21 | €0 | - | = | |
| Tangible fixed assets | 22/27 | €142,716 | €101,438 | -€41,278 | -28.9% |
| Land and buildings | 22 | €139,369 | €98,821 | -€40,548 | -29.1% |
| Plant, machinery and equipment | 23 | €3,346 | €2,616 | -€730 | -21.8% |
| Financial fixed assets | 28 | €6,407 | €6,407 | = | 0.0% |
| Current assets | 29/58 | €1,486,822 | €1,904,059 | +€417,238 | +28.1% |
| Amounts receivable within one year | 40/41 | €1,475,223 | €1,902,891 | +€427,668 | +29.0% |
| Trade receivables | 40 | €60,524 | €22,691 | -€37,833 | -62.5% |
| Other amounts receivable | 41 | €1,414,699 | €1,880,200 | +€465,501 | +32.9% |
| Cash at bank and in hand | 54/58 | €11,599 | €1,168 | -€10,430 | -89.9% |
| Total equity and liabilities | 10/49 | €1,635,944 | €2,011,903 | +€375,959 | +23.0% |
| Equity | 10/15 | €1,132,978 | €1,040,340 | -€92,638 | -8.2% |
| Contributions | 10/11 | €1,298,244 | €1,298,244 | = | 0.0% |
| Capital | 10 | €1,298,244 | €1,298,244 | = | 0.0% |
| Issued capital | 100 | €1,298,244 | €1,298,244 | = | 0.0% |
| Reserves | 13 | €29,334 | €29,334 | = | 0.0% |
| Non-distributable reserves | 130/1 | €14,364 | €14,364 | = | 0.0% |
| Legal reserve | 130 | €14,364 | €14,364 | = | 0.0% |
| Tax-exempt reserves | 132 | €14,970 | €14,970 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€194,600 | -€287,237 | -€92,638 | -47.6% |
| Amounts payable | 17/49 | €502,966 | €971,563 | +€468,597 | +93.2% |
| Amounts payable after more than one year | 17 | €97,566 | - | -€97,566 | |
| Financial debts | 170/4 | €97,566 | - | -€97,566 | |
| Amounts payable within one year | 42/48 | €398,011 | €969,301 | +€571,289 | +144% |
| Current portion of amounts payable after more than one year | 42 | €52,527 | - | -€52,527 | |
| Financial debts | 43 | €285,334 | €749,456 | +€464,122 | +163% |
| Credit institutions | 430/8 | €285,334 | €749,456 | +€464,122 | +163% |
| Trade debts | 44 | €59,983 | €39,690 | -€20,293 | -33.8% |
| Suppliers | 440/4 | €59,983 | €39,690 | -€20,293 | -33.8% |
| Other amounts payable | 47/48 | €167 | €180,155 | +€179,988 | +107,462% |
| Accrued charges and deferred income | 492/3 | €7,388 | €2,262 | -€5,126 | -69.4% |
| Non-recurring operating income | 76A | €160,017 | - | -€160,017 | |
| Remuneration, social security and pensions | 62 | €40,003 | - | -€40,003 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €149,793 | €47,522 | -€102,271 | -68.3% |
| Other operating charges | 640/8 | €6,704 | €4,696 | -€2,008 | -30.0% |
| Non-recurring operating charges | 66A | €9,990 | - | -€9,990 | |
| Gross operating margin | 9900 | €160,783 | -€9,779 | -€170,562 | |
| Operating profit (loss) | 9901 | -€45,706 | -€61,996 | -€16,290 | -35.6% |
| Financial charges | 65/66B | €15,631 | €30,642 | +€15,011 | +96.0% |
| Recurring financial charges | 65 | €15,631 | €30,642 | +€15,011 | +96.0% |
| Profit (loss) for the period before taxes | 9903 | -€61,337 | -€92,638 | -€31,301 | -51.0% |
| Profit (loss) for the period | 9904 | -€61,337 | -€92,638 | -€31,301 | -51.0% |
| Profit (loss) for the period to be appropriated | 9905 | -€61,337 | -€92,638 | -€31,301 | -51.0% |
Source: filed annual accounts (NBB), financial years ended 31 December 2023 and 31 December 2024. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 17 October 2026 via checked.be.